We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
High prevalence of Y-box protein-1/p18 fragment in plasma of patients with malignancies of different origin.
- Authors
Tacke, Frank; Galm, Oliver; Kanig, Nicolas; Yagmur, Eray; Brandt, Sabine; Lindquist, Jonathan A.; Eberhardt, Christiane S.; Raffetseder, Ute; Mertens, Peter R.
- Abstract
Background Expression of the cold shock protein Y-box protein 1 (YB-1) is associated with deleterious outcome in various malignant diseases. Our group recently showed that the detection of an 18 kDa YB-1 fragment (YB-1/p18) in human plasma identifies patients with malignant diseases. We now tested the prevalence, clinical, and diagnostic value of YB-1/p18 detection in common tumors. Methods A newly established monoclonal YB-1 antibody was used to detect YB-1/p18 by immunoblotting in plasma samples from 151 unselected tumor patients, alongside established tumor markers and various diagnostic measures, during evaluation for a cancerous disease and in follow-up studies after therapeutic interventions. Results Circulating YB-1/p18 was detected in 78% of patients having a tumor disease. YB-1/p18 positivity was highly prevalent in all examined malignancies, including lung cancer (32/37; 87%), breast cancer (7/10; 70%), cancer of unknown primary (CUP; 5/5, 100%) or hematological malignancies (42/62; 68%). Positivity for YB-1/p18 was independent of other routine laboratory parameters, tumor stage, or histology. In comparison to 13 established tumor markers (cancer antigens 15-3, 19-9, 72-4, and 125; carcinoembryonic antigen; cytokeratin fragments 21-1; neuron-specific enolase; alpha-fetoprotein; beta-2-microglobulin; squamous cell carcinoma antigen; thymidine kinase; tissue polypeptide antigen; pro-gastrin-releasing peptide), YB-1/p18 detection within serum samples was the most sensitive general parameter identifying malignant disorders. YB-1/p18 concentrations altered during therapeutic interventions, but did not predict prognosis. Conclusions Plasma YB-1/p18 detection has a high specific prevalence in malignancies, thereby providing a novel tool for cancer screening independent of the tumor origin.
- Subjects
DISEASE prevalence; CARRIER proteins; CANCER patients; COLD shock proteins; HEALTH outcome assessment; CANCER diagnosis; MONOCLONAL antibodies; TUMOR markers
- Publication
BMC Cancer, 2014, Vol 14, Issue 1, p1
- ISSN
1471-2407
- Publication type
Article
- DOI
10.1186/1471-2407-14-33